Financial and Clinical Benefits of RSV Immunization

EP: 1.Overview of RSV Patient Populations

EP: 2.Complications Associated with RSV Infections

EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

EP: 4.RSV: Risk Factors and How It’s Spread

EP: 5.Diagnostic Practices for RSV

EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients

EP: 7.Shared Decision-Making Practices in RSV

Now Viewing

EP: 8.Financial and Clinical Benefits of RSV Immunization

EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

EP: 10.Addressing Vaccine Fatigue

EP: 11.Identifying Patients Eligible for RSV Vaccine

EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines

EP: 13.Improving Insurance Coverage for RSV Vaccines

EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation

EP: 15.Key Takeaways on RSV Vaccination

Video content above is prompted by the following questions:

• With RSV vaccines newly approved, what are the financial and clinical goals associated with immunizing against RSV?
• Have payers activated early coverage for the adult RSV vaccines since they entered to reduce costs?
  • How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?